Literature DB >> 6138058

Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients.

W G O'Callaghan, M S Laher, K McGarry, E O'Brien, K O'Malley.   

Abstract

As little is known of the antihypertensive efficacy or renal haemodynamic effects of beta-adrenoceptor blocking drugs in the elderly we studied two such drugs, atenolol and nadolol, in elderly hypertensive patients. Ten patients took part in a placebo-controlled double-blind study of atenolol and 10 received nadolol in a single-blind placebo-controlled study. Treatment phases lasted 12 weeks for atenolol or 10 weeks for nadolol. Blood pressure, effective renal blood flow and glomerular filtration rate data obtained at the end of each treatment phase were analysed. Atenolol lowered mean arterial pressure (mean +/- s.e. mean) from 129.9 +/- 1.5 to 108.2 +/- 2.3 mm Hg (P less than 0.01) while it increased mean effective renal blood flow 512.5 +/- 86.6 to 646.0 +/- 116.1 ml min-1 1.73 m-2 (P less than 0.05). Nadolol reduced mean arterial pressure from 133.2 +/- 2.0 to 113.5 +/- 3 mm Hg (P less than 0.001) but reduced mean effective renal blood flow from 558.8 +/- 32.2 to 446.0 +/- 26.9 ml min-1 1.73 m-2 (P less than 0.05). Glomerular filtration did not alter significantly with either drug. We conclude that beta-adrenoceptor blocking drugs are effective antihypertensive agents in the elderly but have disparate effects on effective renal blood flow perhaps because of differences in cardioselectivity. These data suggest that comparative studies with thiazide diuretics and beta-adrenoceptor blocking drugs are warranted in elderly hypertensives.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138058      PMCID: PMC1428043          DOI: 10.1111/j.1365-2125.1983.tb02187.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension.

Authors:  F R Bühler; F Burkart; B E Lütold; M Küng; G Marbet; M Pfisterer
Journal:  Am J Cardiol       Date:  1975-10-31       Impact factor: 2.778

2.  beta-adrenergic blockade in essential hypertension: reduced renin release despite renal vasoconstriction.

Authors:  J M Sullivan; D F Adams; N K Hollenberg
Journal:  Circ Res       Date:  1976-10       Impact factor: 17.367

3.  Renal function following a single dose of pindolol in hypertensive patients with varying degrees of impairment of renal function.

Authors:  C Heierli; H Thoelen; P Radielovic
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-02

4.  Combination hypotensive therapy with atenolol, bendrofluazide and hydrallazine.

Authors:  R G Wilcox
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

5.  Changes in glomerular filtration rate during long-term treatment with propranolol in patients with arterial hypertension.

Authors:  H Ibsen; P Sederberg-Olsen
Journal:  Clin Sci       Date:  1973-02       Impact factor: 6.124

6.  A computerized cummulative integral method for the precise measurement of the glomerular filtration rate. 1.

Authors:  J D Harries; R R Mildenberger; A S Malowany; K N Drummond
Journal:  Proc Soc Exp Biol Med       Date:  1972-09

7.  [Comparative study of the influence of beta-adrenergic stimulants and adrenergic blocking drugs on renal function in normal humans].

Authors:  G Bufano; L Piacentini
Journal:  Minerva Med       Date:  1969-04-04       Impact factor: 4.806

8.  Effect of norepinephrine, isoproterenol, and adrenergic blockers upon the intrarenal distribution of blood flow.

Authors:  S Carrière
Journal:  Can J Physiol Pharmacol       Date:  1969-02       Impact factor: 2.273

9.  Plasma renin activity after the use of a new beta-adrenergic blocking agent (I.C.I. 66,032).

Authors:  H Aberg
Journal:  Int J Clin Pharmacol       Date:  1974-03

10.  Comparison of the effects of dopamine, isoproterenol, norepinephrine and bradykinin on canine renal and femoral blood flow.

Authors:  J L McNay; L I Goldberg
Journal:  J Pharmacol Exp Ther       Date:  1966-01       Impact factor: 4.030

View more
  7 in total

Review 1.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  The treatment of hypertension in the elderly.

Authors:  M Chellingsworth; D G Beevers
Journal:  Postgrad Med J       Date:  1986-01       Impact factor: 2.401

3.  Intrinsic sympathomimetic activity of cardioselective beta-adrenoceptor blockers and effects on renal function.

Authors:  I G Mackay; A M Macnicol; H J Smith; A D Cumming; M L Watson
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

4.  Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function.

Authors:  A G Dupont; P Vanderniepen; A M Bossuyt; M H Jonckheer; R O Six
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

5.  Multicentre comparison of the antihypertensive effect of acebutolol and hydrochlorothiazide in uncomplicated mild-moderate hypertension in the elderly.

Authors:  A Salvetti; M Lucchini; G Airoldi; M A Cagianelli; G Cinotti; R Cortese; G Diamanti; F Giuntoli; R Pedrinelli; G Pettinà
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  The effect of celiprolol on glomerular filtration rate and renal blood flow in patients with chronic renal impairment and healthy volunteers.

Authors:  R A Robson; P G Bridgman; J E Wells; R R Bailey; K L Lynn
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

Review 7.  How Do Antihypertensive Drugs Work? Insights from Studies of the Renal Regulation of Arterial Blood Pressure.

Authors:  Holly Digne-Malcolm; Matthew C Frise; Keith L Dorrington
Journal:  Front Physiol       Date:  2016-07-29       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.